ArticleiScience2026
2'-Fucosyllactose transactivates EGF receptor in intestinal epithelial cells for prevention of colitis in adulthood.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 2'-Fucosyllactose and its metabolites propionate/butyrate suppress inflammation through a shared TLR4/p38 MAPK-dependent pathwayCurrent research in food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Human milk oligosaccharides (HMOs) benefit growth in infancy. However, mechanisms underlying regulation of host cellular responses by HMOs remain largely unknown. We report that 2'-fucosyllactose (2'-FL), an abundant oligosaccharide in human milk, interacts with a metalloproteinase, ADAM17, on the cell surface and stimulates its catalytic activity for releasing membrane-bound heparin-binding (HB)-EGF, leading to transactivation of epidermal growth factor receptor (EGFR) in intestinal epithelial cells (IECs). Further, this direct effect of 2'-FL on IECs contributed to preserving tight junctions and attenuating apoptosis in response to proinflammatory cytokine and oxidative stress. Remarkably, 2'-FL treatment prevented colitis and maintained intestinal epithelial integrity during colonic injury and colitis in wild-type adult mice, which was mitigated in mice with deletion of EGFR in IECs. These findings reveal a molecular mechanism of the direct protection of intestinal epithelium by 2'-FL and discern this effect as an approach for the prevention of intestinal inflammation beyond the early life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.